US 11,945,804 B2
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
Matthew D. Alexander, San Diego, CA (US); Soraya Carrancio, San Diego, CA (US); Matthew D. Correa, San Diego, CA (US); Virginia Heather Sharron Grant, San Diego, CA (US); Joshua Hansen, La Jolla, CA (US); Roy L. Harris, San Diego, CA (US); Dehua Huang, San Diego, CA (US); Timothy S. Kercher, San Diego, CA (US); Antonia Lopez-Girona, San Diego, CA (US); Mark A. Nagy, Encinitas, CA (US); and Veronique Plantevin-Krenitsky, San Diego, CA (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on May 12, 2022, as Appl. No. 17/743,313.
Application 17/743,313 is a division of application No. 16/390,815, filed on Apr. 22, 2019, granted, now 11,358,952.
Claims priority of provisional application 62/661,525, filed on Apr. 23, 2018.
Prior Publication US 2022/0306611 A1, Sep. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/14 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61P 35/00 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 407/14 (2006.01); C07D 417/14 (2006.01); C07D 491/08 (2006.01); C07D 491/10 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01)
CPC C07D 403/14 (2013.01) [A61P 35/00 (2018.01); C07D 407/14 (2013.01)] 23 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof,
wherein:
Ring A is an azetidyl optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl, OR1, CON(R2)2, SO2(C1-4 alkyl), N(R2)SO2(C1-4 alkyl), —(C0-3 alkyl)-(C3-7 cycloalkyl), (non-aromatic heterocyclyl), aryl, heteroaryl, O-aryl, O-heteroaryl, and C(O)aryl; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more of halogen, oxo, amido, and cyano; wherein R1 is H, C1-6 alkyl optionally substituted with one or more of halogen, or —(C0-3 alkyl)-(C3-7 cycloalkyl); and each R2 is independently H, or C1-6 alkyl;
each R is independently C1-3 alkyl optionally substituted with one or more of halogen, or halogen; and
n is 0, 1, 2, 3 or 4.